Tag: bioconjugation

Axplora announced the completion of its first research and development batches of exatecan, a camptothecin-class topoisomerase I inhibitor, to establish an additional European source for antibody-drug conjugate (ADC) developers [1]. The company said exatecan development and manufacture are based at its Farmabios site in Gropello Cairoli, Italy, and linked to payload-linker development and bioconjugation operations at its Novasep CDMO site in Le Mans, France [1]. Validation batches are targeted before the end of 2026, with initial GMP supply targeted for late 2027 [1].

Antibody Drug Conjugates (ADCs) are biopharmaceutical drugs which are designed to treat cancer by targeting and killing the cancerous cells while leaving the healthy...

Lonza is expanding its bioconjugation capabilities at its Visp in Switzerland. The expansion adds two production suites to the existing conjugation facility providing development...

Lonza, in a statement, confirmed signing a strategic collaboration for bioconjugation with a global biopharma company. Under the terms of the agreement, Lonza will construct...

WuXi Biologics ("WuXi Bio") (2269.HK), a leading global open-access biologics technology platform company offering end-to-end solutions for biologics discovery, development and manufacturing, announced that...

A 'downstream bioconjugation' method may present a new model in antibody-drug conjugate development and manufacturing. In contrast to the existing approaches – which undertake...

UK-based ADC Biotechnology has secured investment for the construction of an $11 million* bioconjugation facility at its new site in Deeside, North Wales, UK. The...

Thius week, following the World ADC Summit in Berlin, Germany, Novasep, a leading supplier of services and technologies for the life sciences industry, announced...

Lyon (France) -based Novasep, a leading supplier of services and technologies for the life sciences industry is building a new synthesis laboratory and a...

Biopharmaceutical contract development and manufacturing organization (CDMO) Ajinomoto Althea earlier today announced that it is expanding its existing biological drug product manufacturing operations to include highly...